Comparative Pharmacology
Head-to-head clinical analysis: LIALDA versus ROWASA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIALDA versus ROWASA.
LIALDA vs ROWASA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mesalamine, the active ingredient in Lialda, is an anti-inflammatory agent that inhibits prostaglandin production and leukotriene synthesis, and reduces cytokine production in the colonic mucosa.
5-aminosalicylic acid (5-ASA) inhibits prostaglandin and leukotriene synthesis, reduces neutrophil chemotaxis, and scavenges reactive oxygen species, thereby exerting anti-inflammatory effects on the colonic mucosa.
2-4 tablets (2.4-4.8 g) orally once daily. Each tablet contains 1.2 g mesalamine.
Rectal suspension enema: 4 g (60 mL) once daily at bedtime, retained for at least 8 hours. Rectal suppository: 500 mg twice daily (one in the morning and one at bedtime).
None Documented
None Documented
Terminal elimination half-life of mesalamine is approximately 12 hours (range 8-15 hours) for the sustained-release formulation; clinical steady-state is reached within 3-5 days.
Terminal elimination half-life of mesalamine (5-ASA) is approximately 0.5-2 hours; N-acetyl-5-ASA half-life is 5-10 hours. Rectal administration prolongs local retention without altering systemic half-life.
Renal (primarily, as N-acetyl-5-aminosalicylic acid, about 80%) and fecal (as unchanged mesalamine, about 20%).
Renal: approximately 78% (primarily N-acetyl-5-ASA and unchanged 5-ASA). Fecal: approximately 20% (unabsorbed drug). Biliary: negligible (<1%).
Category C
Category C
Aminosalicylate
Aminosalicylate